ArticleVaccines2026
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Among Elderly Adults in Changshu City: A Multilevel Cluster Analysis.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundElderly individuals are at high risk for pneumococcal pneumonia, and vaccination is crucial for prevention. This study aims to evaluate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in elderly individuals aged 65-84 years in Changshu City, identify key target groups, and explore potential factors influencing vaccine effectiveness.
methodsA multilevel cluster sampling method was employed to survey 2310 elderly individuals aged 65-84 years from four randomly selected towns/streets in Changshu City. Data were collected through face-to-face questionnaires and integrated with the immunization records system and electronic health records. Chi-square tests and multivariable logistic regression models were used to assess the association between PPV23 vaccination and pneumonia risk, with adjustments for potential confounding factors.
resultsPPV23 vaccination significantly reduced the risk of pneumonia (adjusted OR = 0.69, 95% CI = 0.50-0.94,
conclusionsPPV23 vaccination is effective in reducing pneumonia risk among elderly adults, particularly in specific subgroups. Future vaccination strategies should prioritize targeted programs for high-risk groups to improve coverage and effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.